S rq Seventeen alkylamine ammine dicarboxylatodichloroplatinum(IV) complexes of general sucture c,t,c[tCAO COR1)2NH3(RNH2)J where R = aiphatic or aliyclic and RI = aiphatic or aromatic, have ben evahlated against L1210 cell lines with acqured -ssta1c to cisplatin (10-fold), tetraplatin (34-fold) or carboplatin (14-fold) using an in vitro growth-delay assay. All of these compounds overcame cisatin, tetraplatin and carboplatin resistance. Potency i d as the number of carbon atoms in the axial aliphatic ligands (R) increas, for example com JM216 (R = cydohexyl, RI = CHI, ICs, = 1.2 m) with JM274 (R = cydohexyl, RI = n-C4H,, IC,q = 0.05 aM) against the parent sensitive lne (L1210/S). The most active compounds were those possesing aromatic ligands at RI, regardls of whether R = ahphatic or alicycic, for example JM244 (R = n-C3H7, RI = C*H5, ICg = 0.028 am) and JM2644 (R = c-C1H1I, RI = CjHS, IC5n = 0.031 aM) against L12101S. For an alicychc alkylamine series in which R is varied from c-C3H7 to C-C7H13, with RI = n-C,H7 for each compound, cytotoxic potency was maximisd at c-CjH1 (JM221, IC5. = 0.06 FM against L1210/S). Preliminary biochemical sudies, at equitoxic doses, comparing JM221 (0.1FIM) with cisplatin (0.6 aM) identified five times more platinum associated with JM221 treated cells and 1.5 times more platinum bound to the DNA of JM221-treated cells. The lpophilic properies of some of these platinum(V) dicarboxylates may contribute to both the potency and circumvention of rsstance by these compounds.
evahlated against L1210 cell lines with acqured -ssta1c to cisplatin (10-fold), tetraplatin (34-fold) or carboplatin (14-fold) using an in vitro growth-delay assay. All of these compounds overcame cisatin, tetraplatin and carboplatin resistance. Potency i d as the number of carbon atoms in the axial aliphatic ligands (R) increas, for example com JM216 (R = cydohexyl, RI = CHI, ICs, = 1.2 m) with JM274 (R = cydohexyl, RI = n-C4H,, IC,q = 0.05 aM) against the parent sensitive lne (L1210/S). The most active compounds were those possesing aromatic ligands at RI, regardls of whether R = ahphatic or alicycic, for example JM244 (R = n-C3H7, RI = C*H5, ICg = 0.028 am) and JM2644 (R = c-C1H1I, RI = CjHS, IC5n = 0.031 aM) against L12101S. For an alicychc alkylamine series in which R is varied from c-C3H7 to C-C7H13, with RI = n-C,H7 for each compound, cytotoxic potency was maximisd at c-CjH1 (JM221, IC5. = 0.06 FM against L1210/S). Preliminary biochemical sudies, at equitoxic doses, comparing JM221 (0.1FIM) with cisplatin (0.6 aM) identified five times more platinum associated with JM221 treated cells and 1.5 times more platinum bound to the DNA of JM221-treated cells. The lpophilic properies of some of these platinum(V) dicarboxylates may contribute to both the potency and circumvention of rsstance by these compounds.
Cisplatin [cis-diamminedichloroplatinum(II) ] is a valuable anti-cancer drug, particularly for the treatment of ovarian and testicular tumours (Ozols & Young, 1984; Rosenberg, 1985) . However, cilatin-related toxicities, together with the emergene of tumour resistance, has limited its usefulness (Gottlieb & Drewinko, 1975; Krakoff, 1979) . Carboplatin [c-dammicycobl,lI-dicarboxylato)platinum(ll)] was developed as a second-generation platinum drug, which, although devoid of many of the toxic side-effects of cisplatin, retained a similar spectrum of clinical activity (Harrap, 1985; Mangioni et al., 1989) . More recently, attention has switched to the platinum (IV) compounds iproplatin [cis-dichlorotrans-dihydroxo-cas-bis(isopropylamine)platinum (IV)J and tetraplatin [(trans-d,l ,2-diaminocylohexanetetrachloroplatinu(IV) both of which have been intrduced into cinical studies (Bramwell et al., 1985; Schilder et al., 1987) . It has been shown that these platinum(IV) compounds undergo reduction to the platinum(II) species in biological systems (Gibbons et al., 1989; Pendyala et al., 1990 ). This appears to be a requirement for the major event leading to cytotoxicity, i.e. platinum binding to DNA (Pendyala et al., 1988) . Tetraplatin was selected for clinical development following the observation that platinum complexes with a diaminocyclohexane ligand retain activity against cisplatin-resistant L1210 and P388 murine leukaemias (Burchenal et al., 1979; Rose et al., 1982) . Recently, we have shown that ammine/amine (mixed amines) platinum(II) compounds based on the structures of cisplatin and carboplatin and diamminetetrachloroplatinum(IV) overcome acquired resistance to isplatin (10-fold) but not to tetraplatin (34-fold) in L1210 cells (Orr et al., 1993) . However, trans-dihydroxodichloroplatinum(IV) mixed amines together with iproplatin and the parent diammine overcome resistance to both cisplatin and tetraplatin in these ceUl lines. These studies have now been extended to evaluate the potency of novel mne/amine platinum(IV) dicarboxylates against cisplatin-, tetraplatin-and the newly developed carboplatin-resistant (Nicolson et al., 1992) (Giandomenico et al., 1991) . Phenol (Ultra Pure) was obtained from Gibco/ BRL (Uxbridge, Middksex, UK) and all other reagent chemicals from Sigma (Poole, Dorset, UK). Cell culture medium and serum were purchased from ICN Flow (High Wycombe, Buckinghamshire, UK).
Cell lines and growth delay/cell survival assays Parent sensitive L1210 murine leukaemia cells and their platinum-resistant counterparts, possessing acqred resistance to either cisplatin (L1210/cis), carboplatin (L1210/ carbo) or tetraplatin (L1210/tetra), were grown in RPMI-1640 medium supplemented with 10% horse serum, 2 mM glutamine and antibiotics (100 U ml-l penicillin and 0.1 mg ml' streptomycin). The development and maintenance of resistance to each agent have been described elsewhere (Nicolson et al., 1992; Orr et al., 1993 (Nicolson et al., 1992) . Plating eficiencies of control cultures were 78% and 93% for L12IO/S and L1210/cis respectively.
Platinuwn associted with whole cells, nuclei and DNA Either cisplatin or JM221 was added to cells which were at a cell density of 2 x I0 ml-'. After 24 h, cells were centrifuged at 800 g for 5 mi, washed once with ice-cold phosphatebuffered saline (PBS) and split into three aliquots for cellular, nuclei and DNA extractions. For cellular platinum levels, cell pellets were resuspended in water (2 x 107cells ml-'), sonicated and platinum levels measured as previously described (Nicolson et al., 1992) . For nuclei preparations, the washed cell pellets (approximately 5 x 107 cells) were resuspended in ice-cold PBS (106ml-') to give a single-cell suspension and Nonidet P40 added to a final concentration of 0.05% (w/v). Tubes were inverted several times and placed on ice for 5 min. Intact nuclei were visualised by light microscopy and counted. This technique resulted in efficient membrane stripping with no loss of nuclei in these cell lines. Following centrifugation at 800 g for 5 min, nuclei were resuspended in water (4 x 107ml-') and sonicated as for cellular platinum. For DNA isolation, frozen cell pellets (approximately 5 x 107 cells) were thawed into 2.5 ml of lysing solution (0.4% SDS, 150 mM sodium chloride, 10 mM EDTA, 1 mg ml-' proteinase K, 10 mM Tris, pH 7.4) and incubated at 65'C for 15 min and then at 37C overnight. Lysates were extracted with an equal volume of phenol reagent (Kirby, 1965) and, following centrifugation at 2,000g for 20 min, the aqueous phase was removed, sodium acetate added (0.3 M final concentration) and nucleic acids precipitated by addition of 2.5 volumes of ethanol. After two washes with 80% ethanoL the nucleic acids were pelleted by centrifugation, dissolved in 4.5 ml of 10 mM Tris-0.1 mM EDTA pH 7.7 and incubated with 25 iLl of RNAse A (10 mg ml-') at 37C for 30min. Solutions were re-extracted with phenol reagent and DNA precipitated and collce as described above. Dried DNA was digested in 250 Id of 0.2% nitric acid at 37C overnight. The platinum content of all three preparations was measured by flameless atomic absorption spectroscopy using a Perkin Elmer 1 IOOB/HGA 700 (detection limit 5 ng ml-'). DNA content was assessed by the measurement of 2'-deoxyribose units by the colorimetric method of Burton (1956) . Approximately 100 lg of DNA was extracted per 107 cells. For direct comparison of results between platinum associated with cell and nuclei sonicates and extracted DNA, the results with the cell sonicates and nuclei were normalised to their DNA rather than protein content. A DNA fraction was prepared from both by a modification of the method of Schmidt and Thannhauser (1945) . Briefly, 0.5ml of sonicate was added to 2.5ml of ice-cold 0.2 M perchloric acid (PCA) and the precipitate collected by centrifugation at 800 g for 10 min. The precipitate was hydrolysed twice in 0.75 ml of 1 M PCA at 70°C for 20 min followed by centrifugation. The two supernatants were combined and the 2'-deoxyribose content measured as referenced above. In the event that a small proportion of RNA may have broken down during the procedure, alkalinehydrolysed RNA was added to the assay and found not to interfere with the measurement of 2'-deoxyribose units. For DNA platination experiments using L1210/S and L1210/cis cells exposed to varying concentrations of cisplatin for 2 h, expenments were initiated at a cell density of 4 x I0 ml-' (I50ml per point) to obtain an optimal cell harvest for the DNA extraction procedure. Comparisons between cellular, nuclei or DNA-associated platinum were carried out using Welch's alternative t-test, owing to the variances between standard deviations and two-tailed P-values caculated. (Table I) , in which the amine ligand was isobutyl and the axial ligands either acetato (JM222) or butyrato (JM223), potency increased about 10-fold with extending the chain length of the axial ligands. When the amine ligand was n-propyl and with aryl substituents on the axial ligands (JM244), the IC50 value was reduced almost 200-fold. The most active compound in the alicyclic series of amne/amine dicarboxylates (axial ligand = butyrato) was JM221 (R = cyclohexyl, Table H). Table III shows the results obtained with cyclohexylamine/ ammines carrying various axial dicarboxylate ligands (aliphatic, branched-chain aliphatic and aromatic). As axial straight-chain aliphatic substituents were extended in a step- wise manner, so the potency of the compounds increased, e.g. comparing JM216, JM231 and JM221 the butyrato axial ligand (JM221) was the most effective. Branched-chain aliphatics were less effective in producing growth delays compared with their straght-chain counterparts. Overall, the most active compounds in Table HI were those with aromatic axial ligands (JM2644 and JM290). The IC_% values of JM2644 and JM290 were similar to the IC5, value of JM244 (aromatic axial ligands, aliphatic amine ligand) in Table I . All of the platinum(IV) ami ne/amine diarboxylates overcame cisplatin, tetraplatin and carboplatin istance in these L1210 lines, resistance factors being in the range of 0.4-2. JM221 was selected for further comparative studies with cisplatin as the most potent of the alicyclic compounds in Table II. Cell survival Cell survival, as measured by colony-forming ability in soft agar following a 2 h exposure to varying concentrations of cisplatin, in the L1210/S and L1210/cis lines has been reported elsewhere (Nicolson et al., 1992) . In order to assess the biochemical parameters associated with longer term exposure to cisplatin or JM221 in the L1210/S and L1210/cis lines, cell survival experiments were carried out following 24 h exposure to either agent (Figure 1 ). The concentrations of compounds that resulted in 25% clonogenic survival were 0.6 Mm cisplatin and 0.1 ps JM221 for L1210/S and 42 pm cisplatin and 0.15M JM221 for L1210/cis. The first three drug treatments were seeted for further biochmical studies.
At these drug concentrations cells continued to cycle through one doubling during the 24 h continuous exposure, and viabilities, as ass by trypan blue dye exclusion, were >90%. JM221 treatment of the L1210/cis line was omitted owing to an apparent lack of cross-resistance in colony assays.
Biochemistry
Following exposure of L1210/S and L1210/cis cells to varying concentratons of cisplatin (up to 100 aum) for 2 h, the L1210/cis line had approximately 50% less platinum associated with the DNA than the sensitive line at all drug concentrations (Figure 2 ). Viability studies (trypan blue dye exclusion) showed both cell lines to be intact following 2 h exposure to 100 LM cisplatin. At 10 pm cisplatin for 2 h, cell survival in clonogenic assays was 4% and 76% for L1210/S and L1210/cis respectively. These studies were extended to the measurement of cellar, nuclei and DNA platinum binding in cells exposed to either cisplatin or JM221 for 24 h at concentrations which resulted in 25% survival. L1210/cis cells exposed to a non-toxic concentration of cisplatin (0.6 lsM) for 24 h were included for comparison with the sensitive line. At equimolar concentrations of cisplatin (0.6 ElM) significantly less platinum was associated with the cells and DNA of the L1210/cis line compared with L1210/S (Table IV) , whereas no statistical difference was shown with nuclei and DNA bining although the means were lower. platinum (nearly 4-fold) and twice as much platinum was associated with the nuclei and DNA of the L1210/cis line. When the sensitive line was exposed to equitoxic concentrations of either cisplatin or JM221, it was evident that nearly five times more platinum was associated with whole cells following JM221 exposure, even though the added drug concentration was 6-fold lower than cisplatin (Table IV) . Although more DNA platination (1.5-fold) was observed after exposure to JM221 compared with cisplatin, there was no significant difference between nuclear platinum concentrations.
Discussio
Recently we showed that, although four series of novel ammine/amine platinum(II) and platinum(lV) complexes, broadly based on the structures of cisplatin, carboplatin, tetraplatin and iproplatin, can overcome acquired resistance to cisplatin in L1210 cells, the only class of compounds which can overcome acquired resistance to tetraplatin is the series of ammine/amine trans-dihydroxodichloroplatinum(IV)
complexes (Orr et al., 1993) . Since this line is also sensitive to the trans-dihydroxodichloroplatinum(IV) parent diammine, it is apparent that the trans-dihydroxodichloro-ligand arrangement alone confers sensitivity, whereas the nature of the amine ligand determines potency. Now we are reporting a novel class of ammine/amine platinum(IV) dicarboxylates which can overcome acquired resistance to cisplatin, tetraplatin and carboplatin in three variant L1210 lines. With these dicarboxylates, it is apparent that the length and substituents of the axial ligands, as well as of the amine ligand, strongly influence potency. For example, extending a straight-chain aliphatic axial ligand from acetato to butyrato increases the potency 14-fold when these compounds possess a branched-chain amine ligand (comparing JM222 with JM223) and 20-fold when these compounds have an alicycic amine ligand (comparing JM216 with JM221). In addition, the cyclohexylamine function confers greater potency on these compounds (4-to 7-fold) than the corresponding branched-chain aliphatic ligand (comparing JM216 with JM222 and JM221 with JM223) . This is in agreement with the results of colleagues who have studied many of these dicarboxylates, including JM216, JM222 and JM221, using a panel of human ovarian cell lines with a broad spectrum of sensitivity to cisplatin (Kelland et al., 1992) . We also found that the most active compounds against the L1210 lines were those possessing aromatic axial ligands. (Hromas et al., 1987; Richon et al., 1987; Waud, 1987; Kraker & Moore, 1988 (Nicolson et al., 1992; Orr et al., 1993) , and other workers have not found a role for elevated metallothioneins in an L1210 line with acquired resistance to cisplatin (Farnworth et al., 1990) . When L1210/S cells were exposed to equitoxic concentrations of either cisplatin or JM221, nearly five times more platinum was associated with the JM221-treated cells even though the cells were exposed to a 6-fold lower concentration of JM221 than of cisplatin. This is probably because of the greater lipophilicity of JM221 (Giandomenico et al., 1991) , and this property may also contribute to the potency of some of these dicarboxylates. However, from the experiments reported here, we cannot determine whether the majority of the platinum is intracellular or merely bound on/in the cell membrane. Certainly, the amount of platinum bound to the DNA of JM221-treated cells (1.5-fold greater than the cisplatin-treated L1210/S cells) does not reflect the quantity of platinum associated with whole cells. In vitro binding studies of cisplatin or of JM221 at 10 lM to calf thymus DNA over 24 h at 37°C showed that six times more cisplatin was bound than JM221 (data not shown). Whether the parent compound or an intracellular platinum(II) or (IV) metabolite binds to the DNA in L1210 cells remains to be determined. Certainly, the L1210/tetra line is cross-resistant to the reduced platinum(II) metabolite JM118 [cis-amminedichloro (cyclohexylamine)platinum(II)], whereas sensitivity is retained with JM221. However, this cross-resistance may be at the level of cellular uptake of compound.
In summary, platinum(IV) dicarboxylates represent another class of platinum-containing agents which overcome acquired resistance to cisplatin, tetraplatin and carboplatin in L1210 cells. All of these lines exhibit reduced uptake of the parent compound. However, studies with the L1210/cis line here suggest that at least one other resistance mechanism exists, possibly at the DNA level. Comparing cisplatin with JM221 in the sensitive line at equitoxic concentrations, it is apparent that the high levels of cellular platinum achieved with JM221 contribute to the potency of this dicarboxylate.
